

Applicant : Katia Georgopoulos et al.  
Serial No. : 09/259,389  
Filed : February 26, 1999  
Page : 2



Attorney's Docket No.: 10287-043001 / MGH 1286.0

hybridization in hybridization solution II can contain: 1 mM Na<sub>2</sub>EDTA; 40 mM NaHPO<sub>4</sub>, pH 7.2; and 1% SDS. At 65°C, using the high stringency wash buffer, employ multiple quick washes (5-8) and immerse in a final wash for 20 minutes.--

In the Claims:

Please amend claims 3-5, 10, 11, and 15.

Sub B1  
3. (Amended) The nucleic acid of claim 1, wherein the nucleic acid hybridizes under high stringency conditions to the nucleotide sequence of SEQ ID NO:1, 3, or 5 [a nucleic acid which encodes a Helios polypeptide, or a complement thereof].

A2  
4. (Amended) The nucleic acid of claim 1, wherein the nucleic acid encodes a polypeptide that reacts with an antibody specific for the polypeptide of SEQ ID NO:2, 4, or 6 [a Helios polypeptide].

Sub B2  
5. (Amended) A substantially pure nucleic acid which encodes a fragment of the polypeptide of SEQ ID NO:2, 4, or 6 [a Helios polypeptide] of at least 60 amino acids in length.

Sub B3  
10. (Amended) A vector comprising the nucleic acid of any of claims 1, 2, 3, 4, or 5 [1-5].

11. (Amended) A cell comprising the nucleic acid of any of claims 1, 2, 3, 4, or 5 [1-5].

A4  
15. (Amended) A method of treating an animal for a disorder associated with misexpression of Helios comprising administering a therapeutically active amount of an Helios polypeptide, a cell selected for the expression of a product of an Helios gene, or a nucleic acid encoding an Helios peptide to the animal.

REMARKS

Claims 1-17 are pending in the application, claims 6-9, 12, 14, and 17 having been withdrawn from consideration. Claims 3-5, 10, 11, and 15 have been amended. Applicants will